Noticias de KOD
Noticias del mercado
Últimas noticias sobre KOD — 235 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Kodiak Sciences Inc surged as pivotal clinical trial progress fueled investor optimism, and its stocks have been trading up by 8.56 percent. Key Takeaways Shares of Kodiak Sciences (KOD) exploded between roughly 100% and 190% after Zenkuda and tabirafusp-ted hit Phase 3 endpoints in wet age-related
Second-quarter loss reached USD 1.05 per share. Kodiak Sciences stock costs EUR 77.04 on October 15,
Kodiak Sciences Inc subió a medida que el progreso de los ensayos clínicos fundamentales alimentó el optimismo de los inversores, y sus acciones han subido un 8,56 por ciento. Conclusiones clave Las acciones de Kodiak Sciences (KOD) se dispararon entre aproximadamente un 100% y un 190% después de que Zenkuda y tabirafusp-ted alcanzaran los criterios de valoración de la fase 3 en relación con la edad húmeda.
2026-10-10. The following slide deck was published by Kodiak Sciences Inc.
Loss reached USD 65.6 million in second quarter of 2026. Kodiak Sciences stock costs EUR 81.04 on Oc
Interactive Chart for Kodiak Sciences Inc. (KOD), analyze all the data with a huge range of indicators.
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).
DAYBREAK met its primary endpoint for both treatments, with non-inferior vision gains vs. aflibercept at Year 1; GLOW2 and APEX data are scheduled.
Página 4 de 12